PROGRAM CHAIR

Shubham Pant, MD
Professor
Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas

PROGRAM OVERVIEW

The enduring activity is designed to enhance the target healthcare professionals’ (HCPs) proficiency in applying current guidelines for HER2 testing in patients with gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC). By exploring the efficacy of HER2-targeted therapies for HER2-positive GEA and BTC, the activity seeks to equip HCP’s with the knowledge to develop effective treatment plans and provide robust support for patients experiencing adverse events associated with these therapies.

TARGET AUDIENCE

This activity is designed to educate oncology nurses, nurse practitioners (NPs) and physician assistants (PAs) involved in the care of patients with HER2 overexpressing GEA and BTC.

LEARNING OBJECTIVES

• Apply best practices for HER2 testing in patients with GEA and BTC, based on current guidelines
• Summarize the efficacy of HER2-targeted therapies in patients with HER2-positive GEA or BTC
• Plan effective support for patients experiencing AEs associated with HER2-targeted treatment for GEA or BTC

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hour.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer-reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
• Tom Bregartner, MBA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
• Vaidehee Deshpande, MD, Medical Director for Med Learning Group, has nothing to disclose.
• A medical reviewer from CME Peer Review LLC, has nothing to disclose.
• Sarah Milano, RN, has nothing to disclose.
• Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
• Jessica Feygin-Samuels, Program Manager for Med Learning Group, has nothing to disclose.
• Kristen Marks, Program Coordinator for Med Learning Group, has nothing to disclose.
• Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASED DATE: August 08, 2025
EXPIRATION DATE: August 08, 2026

Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.